Athenex (ATNX) Earning Somewhat Positive Press Coverage, Accern Reports
Media coverage about Athenex (NASDAQ:ATNX) has been trending somewhat positive on Wednesday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Athenex earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.4005691868578 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Athenex (NASDAQ:ATNX) opened at 18.70 on Wednesday. Athenex has a 1-year low of $11.21 and a 1-year high of $20.79. The firm’s market capitalization is $1.07 billion. The company has a 50-day moving average of $16.36 and a 200-day moving average of $16.35.
Athenex (NASDAQ:ATNX) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.88) EPS for the quarter. The business had revenue of $4.60 million for the quarter.
Separately, Deutsche Bank AG started coverage on shares of Athenex in a report on Monday, July 10th. They set a “buy” rating and a $20.00 price target on the stock.
COPYRIGHT VIOLATION WARNING: “Athenex (ATNX) Earning Somewhat Positive Press Coverage, Accern Reports” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/athenex-atnx-earning-somewhat-positive-press-coverage-accern-reports/1543949.html.
In other news, Director Song-Yi Zhang acquired 328,637 shares of Athenex stock in a transaction on Monday, June 19th. The shares were purchased at an average cost of $11.00 per share, for a total transaction of $3,615,007.00. Following the completion of the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $44,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Johnson Yiu Nam Lau acquired 25,200 shares of Athenex stock in a transaction on Monday, June 19th. The shares were purchased at an average price of $11.00 per share, for a total transaction of $277,200.00. Following the completion of the purchase, the chief executive officer now directly owns 2,722,722 shares of the company’s stock, valued at $29,949,942. The disclosure for this purchase can be found here.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.